Discover a study exploring cutting-edge melanoma vaccines and their potential to enhance long-term survival in high-risk patients.

The FDA has issued a CRL to Replimmune regarding the BLA for vusolimogene oderparepvec (RP1) in combination with nivolumab for advanced melanoma.

A Northeastern University researcher has identified a way to target two of the deadliest cancer types, melanoma and triple ...